China
Africa
Explore chapters and articles related to this topic
Nonketotic hyperglycinemia
Published in William L. Nyhan, Georg F. Hoffmann, Aida I. Al-Aqeel, Bruce A. Barshop, Atlas of Inherited Metabolic Diseases, 2020
William L. Nyhan, Georg F. Hoffmann, Aida I. Al-Aqeel, Bruce A. Barshop
There is currently no effective treatment known for variant nonketotic hyperglycinemia. Treatment with high dose lipoic acid has not been successful, either in vitro or in vivo [62–63].
Basic Facts about Micronutrients
Published in Kedar N. Prasad, Micronutrients in Health and Disease, 2019
Alpha-lipoic acid: Alpha-lipoic acid, also called thioctic acid, exists in two forms: R-alpha-lipoic acid (natural form) and S-alpha-lipoic acid (synthetic form). It acts as an antioxidant and elevates the levels of glutathione. R-alpha-lipoic acid is found in many vegetables, such as broccoli, yams, potatoes, and brussels sprout. Red meat and organs are rich in alpha-lipoic acid.
Selected Supplements That Support Glycemic Control and Reduce Chronic Inflammation
Published in Robert Fried, Richard M. Carlton, Type 2 Diabetes, 2018
Robert Fried, Richard M. Carlton
A number of “Select clinical trials using lipoic acid (LA),” listing doses administered to human participants, and the parameters observed, including possible health effects, can be found in a table in Shay, Moreau, Smith et al. (2009) (Biochimica et Biophysica Acta, Oct; 1790(10): 1149–1160; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2756 298/table/T3/; accessed 10.29.17).
The synergic effects of alpha-lipoic acid supplementation and electrical isotonic contraction on anthropometric measurements and the serum levels of VEGF, NO, sirtuin-1, and PGC1-α in obese people undergoing a weight loss diet
Published in Archives of Physiology and Biochemistry, 2022
Majid Mohammadshahi, Elahe Zakizadeh, Kambiz Ahmadi-Angali, Majid Ravanbakhsh, Bijan Helli
Obesity has been dramatically increasing worldwide, with a prevalence of 600 million obese adults (Shay et al. 2009; Holdsworth et al. 2013; Ng et al. 2014). Numerous factors including genetics and lifestyle are strongly associated with obesity and overweight (Manco and Dallapiccola 2012). Recent studies reported the anti-obesity effects of Alpha-lipoic acid (α-LA) (Kim et al. 2004, 2008; Prieto-Hontoria et al. 2009). Alpha-LA is naturally found in dietary sources such as meat, spinach, and broccoli and plays a key role of mitochondrial energy metabolism as a cofactor for mitochondrial enzymatic complexes such as pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase (Prieto-Hontoria et al. 2009). Pyruvate dehydrogenase complex (PDC) is a multifunctional enzyme complex that converts pyruvate into acetyl-CoA (Kim et al. 2004, Prieto-Hontoria et al. 2009). α-LA supplementation can prevent weight gain with decreasing adipose tissue size and increasing energy expenditure (Kim et al. 2008). α-LA supplementation can reduce body weight and modulates the blood glucose levels, thereby improving the insulin sensitivity and reducing the risk factors of cardiovascular disease(Udupa et al. 2012). However, previous studies from clinical trials on α-LA, in terms of design are not consistent.
Evaluating the Lipid-Lowering Effects of α-lipoic Acid Supplementation: A Systematic Review
Published in Journal of Dietary Supplements, 2020
Nicole Erickson, Michelle Zafron, Scott V. Harding, Christopher P.F. Marinangeli, Todd C. Rideout
We noted considerable variability in reported lipid responses to α-lipoic acid supplementation between the included studies. Much of this variability may be expected given variations in experimental design factors, including background diet and α-lipoic acid supplementation level. The supplementation level of the included studies was broad (ranging from 300 to 1,200 mg/d); however, most studies (n = 9) were conducted with a supplementation level of 600 mg/d (Chang et al. 2007; de Oliveira et al. 2011; El-Farok et al. 2013; El-Nabarawy et al. 2010; Khabbazi et al. 2012; Manning et al. 2013; Marangon et al. 1999; Mohammadi et al. 2017; Okanovic et al. 2015; Sun et al. 2012). Only two studies included in this review examined a dose response to α-lipoic acid. However, both reports, Koh et al. (Koh et al. 2011) (1,200 or 1,800 mg/d) and Porasuphatana et al. (Porasuphatana et al. 2012) (300, 600, 900, and 1,200 mg/d) reported no changes in blood lipid parameters at any α-lipoic acid dose. Thus, additional studies are required to more fully assess potential dose responses to α-lipoic acid supplementation.
α-Lipoic acid, functional fatty acid, as a novel therapeutic alternative for central nervous system diseases: A review
Published in Nutritional Neuroscience, 2019
Fatemeh Seifar, Mohammad Khalili, Habib Khaledyan, Shirin Amiri Moghadam, Azimeh Izadi, Amirreza Azimi, Seied Kazem Shakouri
In 1951, α-lipoic acid (ALA) was identified as an essential component of energy metabolism, with the redox status of cells attracting the interest of researchers.1 In cells, LA is reduced by an NADH-dependent reaction with lipoamide dehydrogenase, forming dihydrolipoic acid (DHLA) within the mitochondria.2 Both the oxidized and reduced (DHLA) forms of ALA have antioxidant properties. A healthy human body can synthesize enough ALA, which is associated with genomic regulation of intrinsic antioxidant and anti-inflammatory pathways.3 However, aging and some diseases may diminish the level of ALA content in the body.4 LA is available in plant sources, such as spinach, broccoli and tomatoes, and in animal tissue including kidney, heart, and liver with the highest concentrations.5 Nowadays, commercial LA is composed of R- and S-enantiomers with a 1:1 ratio, and has been used as therapeutic supplement in the treatment of several neurologic and metabolic diseases.6 Recently, there has been considerable attention to the effectiveness of lipoic acid (LA) therapy in central nervous system (CNS) diseases. Therefore, researchers have begun to examine whether it can be considered as a new medication for Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis, stroke, and spinal cord injury (SCI). In this spirit, this review is aimed at evaluating ALA and its potential therapeutic role in CNS diseases.